ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19
Infectious diseases remain a problem throughout the world. The outbreak of sudden acute respiratory syndrome coronavirus 2 (SARS-Co V-2) has infected more than 640 million people worldwide. SARS-Co V-2 causes the disease COVID-19. Mutations in the SARS-CoV-2 S spike protein enable SARS-CoV-2 variants to escape neutralizing monoclonal antibodies produced from previous infection with SARS-CoV2 or by vaccination. The present invention provides antibodies that bind to the SARS-Co V-2 Spike (S) protein. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using the aforementioned antibodies that bind to the SARS-CoV-2 Spike (S) protein.
1 . An antibody or fragment thereof that binds to a sudden acute respiratory syndrome coronavirus 2 (CoV) Spike (S) glycoprotein, wherein the antibody or fragment thereof comprises:
(i) a variable light chain complementarity-determining region 1 (VL CDR1) with at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity to a sequence selected from the group consisting of SEQ ID NOS: 11-14 and 76;
(ii) a variable light chain complementarity-determining region 2 (VL CDR2) with at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity to a sequence selected from the group consisting of SEQ ID NOS: 15-18 and 77;
(iii) a variable light chain complementarity-determining region 3 (VL CDR3) with at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity to a sequence selected from the group consisting of SEQ ID NOS: 19-22 and 78;
(iv) a variable heavy chain complementarity-determining region 1 (VH CDR1) with at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity to a sequence selected from the group consisting of SEQ ID NOS: 23-26 and 79;
(v) a variable heavy chain complementarity-determining region 2 (VH CDR2) with at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity to a sequence selected from the group consisting of SEQ ID NOS: 27-30 and 80; and
(vi) a variable heavy chain complementarity-determining region 3 (VH CDR3) with at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity to a sequence selected from the group consisting of SEQ ID NOS: 31-34 and 81.
2 . An antibody or fragment thereof that binds to a sudden acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike (S) protein, wherein the antibody or fragment thereof comprises:
(i) a variable heavy (VH) domain comprising an amino acid sequence with at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to a polypeptide of SEQ ID NOS: 5-8 and 75; and
(ii) a variable light (VL) domain comprising an amino acid sequence with at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to a polypeptide of any one of SEQ ID NOS: 1-4 and 74.
3 . The antibody or fragment thereof of claim 1 , wherein the antibody or fragment thereof comprises:
(i) a variable heavy (VH) domain comprising an amino acid sequence with at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to a polypeptide of SEQ ID NOS: 5-8 and 75; and
(ii) a variable light (VL) domain comprising an amino acid sequence with at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to a polypeptide of any one of SEQ ID NOS: 1-4 and 74.
4 . The antibody or fragment thereof of claim 2 , wherein the antibody or fragment thereof comprises:
(i) a variable light chain complementarity-determining region 1 (VL CDR1) with at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity to a sequence selected from the group consisting of SEQ ID NOS: 11-14 and 76;
(ii) a variable light chain complementarity-determining region 2 (VL CDR2) with at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity to a sequence selected from the group consisting of SEQ ID NOS: 15-18 and 77;
(iii) a variable light chain complementarity-determining region 3 (VL CDR3) with at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity to a sequence selected from the group consisting of SEQ ID NOS: 19-22 and 78;
(iv) a variable heavy chain complementarity-determining region 1 (VH CDR1) with at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity to a sequence selected from the group consisting of SEQ ID NOS: 23-26 and 79;
(v) a variable heavy chain complementarity-determining region 2 (VH CDR2) with at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity to a sequence selected from the group consisting of SEQ ID NOS: 27-30 and 80; and
(vi) a variable heavy chain complementarity-determining region 3 (VH CDR3) with at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity to a sequence selected from the group consisting of SEQ ID NOS: 31-34 and 81.
5 . The antibody or fragment thereof of claim 4 , wherein the antibody or fragment thereof is selected from the group consisting of: a VH CDR1 according to SEQ ID NOS: 23-26, 79, a V H CDR2 according to SEQ ID NOS: 27-30, 80, a V H CDR3 according to SEQ ID NOS: 31-34, 81, a VL CDR1 according to SEQ ID NOS: 11-14,76, a VL CDR2 according to SEQ ID NOS: 15-18,77, and a VL CDR3 according to SEQ ID NOS: 19-22, 78.
6 - 9 . (canceled)
10 . The antibody or fragment thereof of claim 4 , wherein the antibody or fragment thereof is selected from the group consisting of:
(i) a VH comprising the amino acid sequence of SEQ ID NOS:5-8, 75; and
(ii) a VL comprising the amino acid sequence of SEQ ID NOS: 1-4, 74.
11 - 14 . (canceled)
15 . The antibody or fragment thereof of claim 4 , wherein the antibody or fragment thereof is a monoclonal antibody, a Fab, F(ab′) 2 , Fab′, a scFv, or a single domain antibody (sdAb).
16 . The antibody or fragment thereof of claim 4 , wherein the antibody comprises a human IgG1 or IgG4 domain.
17 . The antibody or fragment thereof of claim 4 , wherein the antibody or fragment thereof has an equilibrium dissociation constant (K D ) for a CoV S glycoprotein or variant thereof of 50 nM or less, 10 nM or less, 1 nM or less, 0.5 nM or less, 0.1 nM or less, 0.05 nM or less, 0.01 nM or less, or 0.001 nM or less.
18 . The antibody or fragment thereof of claim 4 , wherein the antibody or fragment thereof binds to a CoV S glycoprotein or variant thereof with an equilibrium dissociation constant (Kd) of less than 1.0×10 −9 moles per liter (M), less than 1.0×10 −10 M, less than 1.0×10 −11 M, or less than 1.0×10 −12 M.
19 . The antibody or fragment thereof of claim 4 , wherein the antibody or fragment thereof binds to one or more CoV S polypeptides with at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to a polypeptide according to any one of SEQ ID NOS: 9, 10, 35-43, 72-73, 90-139, and 145-147.
20 - 21 . (canceled)
22 . The antibody or fragment thereof of claim 4 , wherein the antibody or fragment thereof binds to an epitope on a CoV S glycoprotein, wherein the epitope comprises amino acids 476, 485, 486, 487, and 489 of the CoV S glycoprotein of SEQ ID NO: 10.
23 . (canceled)
24 . The antibody or fragment thereof of claim 4 , wherein the antibody or fragment thereof binds to an epitope on a CoV S glycoprotein, wherein the epitope comprises amino acids 378 and 385 of the CoV S glycoprotein of SEQ ID NO: 10.
25 . The antibody or fragment thereof of claim 4 , wherein the antibody or fragment thereof binds to an epitope on a CoV S glycoprotein, wherein the epitope comprises amino acids 444, 445, 446, and 448 of the CoV S glycoprotein of SEQ ID NO: 10.
26 - 28 . (canceled)
29 . A pharmaceutical composition, comprising an antibody or fragment thereof of claim 4 and a pharmaceutically-acceptable carrier.
30 - 36 . (canceled)